Microvascular Therapeutics Appoints Charles Garrison, MD, to Scientific Advisory Board
Dr Charles Garrison, an experienced pathologist, biotechnology entrepreneur, and life sciences investor will advise MVT on scientific and medical development as new Scientific Advisory Board member.
Tucson, AZ, September 14, 2026 --(PR.com)-- Microvascular Therapeutics, Inc. (MVT), a clinical-stage biotechnology company developing innovative microbubble-based therapies and diagnostic agents, today announced the appointment of Charles Garrison, MD, to its Scientific Advisory Board.
Dr. Garrison is certified by the American Board of Pathology in Anatomic and Clinical Pathology and previously served as Director of Pathology Services at West Paces Medical Center in Atlanta. He is a Fellow of both the American Society for Clinical Pathology and the College of American Pathologists.
In addition to his medical career, Dr. Garrison is a serial entrepreneur who has founded multiple life sciences companies, including Genetics and Laboratory Medicine Inc., The Georgia Tissue Bank, Helical Sciences Laboratory, and Cell Dynamics LLC. Several of these businesses were subsequently acquired by larger healthcare organizations.
Following his retirement from clinical practice, Dr. Garrison became an active angel investor and has invested in more than 70 startup companies spanning biotechnology, biopharmaceuticals, and medical devices. He is also a member of Keiretsu Forum Northwest in Vancouver.
“Charles combines deep medical and pathology expertise with the perspective of a successful life sciences entrepreneur and highly experienced early-stage healthcare investor,” said Evan Unger, MD, CEO and Executive Chairman of Microvascular Therapeutics. “His experience evaluating technologies from the scientific, clinical, and commercial perspectives will be particularly valuable as we advance our therapeutic programs, including Solv and NanoBlate.”
“I am delighted to join the Scientific Advisory Board of Microvascular Therapeutics,” said Dr. Garrison. “The company’s microbubble and ultrasound technologies have the potential to create new approaches to both diagnosis and therapy. I look forward to working with the MVT team as these programs move forward.”
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation microbubble and phase-shift microbubble technologies for diagnostic and therapeutic applications. The company’s pipeline includes CardiSon™, a next-generation ultrasound enhancing agent; Solv™, a therapeutic phase-shift microbubble platform being developed for microvascular obstruction and thrombotic cardiovascular disease; and NanoBlate™, an ultrasound-activated platform being developed for nonthermal tumor ablation and other therapeutic applications. MVT’s founders and team have extensive experience in the development of ultrasound contrast agents and microbubble therapeutics.
Dr. Garrison is certified by the American Board of Pathology in Anatomic and Clinical Pathology and previously served as Director of Pathology Services at West Paces Medical Center in Atlanta. He is a Fellow of both the American Society for Clinical Pathology and the College of American Pathologists.
In addition to his medical career, Dr. Garrison is a serial entrepreneur who has founded multiple life sciences companies, including Genetics and Laboratory Medicine Inc., The Georgia Tissue Bank, Helical Sciences Laboratory, and Cell Dynamics LLC. Several of these businesses were subsequently acquired by larger healthcare organizations.
Following his retirement from clinical practice, Dr. Garrison became an active angel investor and has invested in more than 70 startup companies spanning biotechnology, biopharmaceuticals, and medical devices. He is also a member of Keiretsu Forum Northwest in Vancouver.
“Charles combines deep medical and pathology expertise with the perspective of a successful life sciences entrepreneur and highly experienced early-stage healthcare investor,” said Evan Unger, MD, CEO and Executive Chairman of Microvascular Therapeutics. “His experience evaluating technologies from the scientific, clinical, and commercial perspectives will be particularly valuable as we advance our therapeutic programs, including Solv and NanoBlate.”
“I am delighted to join the Scientific Advisory Board of Microvascular Therapeutics,” said Dr. Garrison. “The company’s microbubble and ultrasound technologies have the potential to create new approaches to both diagnosis and therapy. I look forward to working with the MVT team as these programs move forward.”
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation microbubble and phase-shift microbubble technologies for diagnostic and therapeutic applications. The company’s pipeline includes CardiSon™, a next-generation ultrasound enhancing agent; Solv™, a therapeutic phase-shift microbubble platform being developed for microvascular obstruction and thrombotic cardiovascular disease; and NanoBlate™, an ultrasound-activated platform being developed for nonthermal tumor ablation and other therapeutic applications. MVT’s founders and team have extensive experience in the development of ultrasound contrast agents and microbubble therapeutics.
Contact
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Contact
Categories